---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016818"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:15:04.565565+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics Q1 net loss $4.3M; $9.4M raised; pipeline progress on AJ201, BAER-101, IV tramadol

## Summary
- Net loss $4.3M ($15.40/share) vs $7.5M ($101.57) in Q1 2023; R&D $2.4M, G&A $1.3M.
- Cash $3.2M at Mar 31, up from $1.8M; additional $4.4M gross proceeds from May 2024 warrant exercise.
- AJ201 topline data for Kennedy's Disease expected mid-2024; received FDA agreement on IV tramadol Phase 3 protocol.
- Total $9.4M raised from warrant exercises in Jan and May 2024; 1-for-75 reverse split in April to regain Nasdaq compliance.

## SEC filing metadata
- accession: 0001437749-24-016818
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/atxi20240113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016818
- JSON: https://secwatch.observer/filing/0001437749-24-016818.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016818.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income $4.3 million, or $15.40 per share, EPS $15.40 per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $4.3 million, or $15.40 per share
  - EPS: $15.40 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the first quarter of 2024 was $4.3 million, or $15.40 per share, compared to a net loss of $7.5 million, or $101.57 per share, for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.